Is Drotrecogin alfa (activated) for adults with severe sepsis, cost-effective in routine clinical practice?

被引：0
|
作者：
M Zia Sadique
Richard Grieve
David A Harrison
Brian H Cuthbertson
Kathryn M Rowan
机构：
[1] London School of Hygiene and Tropical Medicine,Department of Health Services Research and Policy, WC1H 9SH
[2] Research Centre,Intensive Care National Audit &WC1H 9HR
[3] Sunnybrook Health Sciences Centre,Department of Critical Care Medicine, M4N 3M5
来源：
Critical Care | / 15卷
关键词：
Severe Sepsis; Critical Care; Additional Data File; Acute Hospital; Critical Care Unit;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 50 条
  • [31] Clinical effectiveness and cost-effectiveness of drotrecogin alfa (activated) (Xigris®) for the treatment of severe sepsis in adults:: a systematic review and economic evaluation
    Green, C
    Dinnes, J
    Takeda, A
    Shepherd, J
    Hartwell, D
    Cave, C
    Payne, E
    Cuthbertson, BH
    HEALTH TECHNOLOGY ASSESSMENT, 2005, 9 (11) : 1 - +
  • [32] Cost effectiveness analysis of drotrecogin alfa (activated) as a treatment for severe sepsis in hospitalised patients
    R Launois
    L Riou Franca
    B Guidet
    P Aegerter
    X Huet
    P Meshaka
    P Pinton
    Critical Care, 6 (Suppl 1):
  • [33] Drotrecogin alfa (Activated) for the treatment of severe sepsis and septic shock
    Rice, TW
    Bernard, GR
    AMERICAN JOURNAL OF THE MEDICAL SCIENCES, 2004, 328 (04): : 205 - 214
  • [34] Drotrecogin alfa (activated) treatment of older patients with severe sepsis
    Ely, EW
    Angus, DC
    Williams, MD
    Bates, B
    Qualy, R
    Bernard, GR
    CLINICAL INFECTIOUS DISEASES, 2003, 37 (02) : 187 - 195
  • [35] Drotrecogin alfa activated as a treatment for severe sepsis in pediatric cancer
    Russo, G.
    La Spina, M.
    Disma, N.
    Astuto, M.
    BONE MARROW TRANSPLANTATION, 2006, 38 (08) : 575 - 576
  • [36] The efficacy of drotrecogin alfa (activated) for the treatment of pediatric severe sepsis
    Giroir, B
    Goldstein, B
    Nadel, S
    Wang, DZ
    Levy, H
    Williams, M
    CRITICAL CARE MEDICINE, 2005, 33 (12) : A152 - A152
  • [37] Drotrecogin alfa activated as a treatment for severe sepsis in pediatric cancer
    G Russo
    M La Spina
    N Disma
    M Astuto
    Bone Marrow Transplantation, 2006, 38 : 575 - 576
  • [38] The safety of drotrecogin alfa (activated) in pediatric patients with severe sepsis
    Goldstein, B
    Williams, M
    Wang, DZ
    Angle, R
    Giroir, B
    CRITICAL CARE MEDICINE, 2005, 33 (12) : A152 - A152
  • [39] Management of patients with severe sepsis, treated by drotrecogin alfa (activated)
    Laterre, PF
    Heiselman, D
    AMERICAN JOURNAL OF SURGERY, 2002, 184 (6A): : 39S - 46S
  • [40] Use of drotrecogin alfa (activated) in older patients with severe sepsis
    Alexander, SL
    Ernst, FR
    PHARMACOTHERAPY, 2006, 26 (04): : 533 - 538
12345